Literature DB >> 32224827

Population Pharmacokinetics of IV Phenobarbital in Neonates After Congenital Heart Surgery.

Céline Thibault1,2, Shavonne L Massey3, Maryam Y Naim1, Nicholas S Abend3, Athena F Zuppa1,2.   

Abstract

OBJECTIVES: To develop a population pharmacokinetic model for IV phenobarbital in neonates following cardiac surgery and perform simulations to identify optimal dosing regimens.
DESIGN: Retrospective single-center pharmacokinetic study.
SETTING: Cardiac ICU at Children's Hospital of Philadelphia. PATIENTS: Consecutive neonates who received greater than or equal to one dose of IV phenobarbital and had greater than or equal to one phenobarbital concentration drawn per standard of care from June 15, 2012, to October 15, 2018.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: A population pharmacokinetic model was developed using nonlinear mixed-effects modeling. Simulations were performed using the final model variables. Optimal phenobarbital loading doses were determined based on attainment of peak and maintenance concentrations between 20 and 40 mg/L. A total of 37 neonates contributed 159 pharmacokinetic samples. The median (range) weight, postmenstrual age, and postnatal age were 3.2 kg (1.3-3.8), 39 2/7 weeks (28 2/7 to 42 6/7), and 5 days (0-26 d), respectively. Twelve patients (32%) were on extracorporeal membrane oxygenation. An one-compartment model best described the data. The final population pharmacokinetic model included (1) weight and postnatal age for clearance and (2) weight, extracorporeal membrane oxygenation, and albumin for volume of distribution. In neonates not on extracorporeal membrane oxygenation, loading doses of 30 and 20 mg/kg reached goal concentration with albumin values less than or equal to 3 and 3.5 mg/dL, respectively. Loading doses of 30 mg/kg reached goal concentration on extracorporeal membrane oxygenation regardless of albumin values. Maintenance doses of 4-5 mg/kg/d reached goal concentration in all neonates.
CONCLUSIONS: In neonates following cardiac surgery, phenobarbital clearance increased with postnatal age. Volume of distribution increased with extracorporeal membrane oxygenation and lower albumin values. Loading doses of 30 mg/kg on extracorporeal membrane oxygenation and 20-30 mg/kg without extracorporeal membrane oxygenation were needed to reach goal concentration based on simulations.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32224827      PMCID: PMC7416482          DOI: 10.1097/PCC.0000000000002341

Source DB:  PubMed          Journal:  Pediatr Crit Care Med        ISSN: 1529-7535            Impact factor:   3.971


  39 in total

1.  The effect of collinearity on parameter estimates in nonlinear mixed effect models.

Authors:  P L Bonate
Journal:  Pharm Res       Date:  1999-05       Impact factor: 4.200

2.  Potential drug sequestration during extracorporeal membrane oxygenation: results from an ex vivo experiment.

Authors:  Nilesh M Mehta; David R Halwick; Brenda L Dodson; John E Thompson; John H Arnold
Journal:  Intensive Care Med       Date:  2007-04-03       Impact factor: 17.440

Review 3.  A pharmacokinetic standard for babies and adults.

Authors:  Nick Holford; Young-A Heo; Brian Anderson
Journal:  J Pharm Sci       Date:  2013-05-06       Impact factor: 3.534

4.  Clinical pharmacokinetics of phenobarbital in neonates.

Authors:  D J Touw; O Graafland; A Cranendonk; R J Vermeulen; M M van Weissenbruch
Journal:  Eur J Pharm Sci       Date:  2000-12       Impact factor: 4.384

5.  Standardized Treatment of Neonatal Status Epilepticus Improves Outcome.

Authors:  Mandy L Harris; Katherine M Malloy; Sheena N Lawson; Rebecca S Rose; William F Buss; Ulrike Mietzsch
Journal:  J Child Neurol       Date:  2016-08-31       Impact factor: 1.987

6.  Estimation of initial phenobarbital dosing in term neonates with moderate-to-severe hypoxic ischaemic encephalopathy following perinatal asphyxia.

Authors:  M Šíma; P Pokorná; J Hartinger; O Slanař
Journal:  J Clin Pharm Ther       Date:  2017-09-22       Impact factor: 2.512

7.  Pharmacokinetics and absolute bioavailability of phenobarbital in neonates and young infants, a population pharmacokinetic modelling approach.

Authors:  Amélie Marsot; Véronique Brevaut-Malaty; Renaud Vialet; Audrey Boulamery; Bernard Bruguerolle; Nicolas Simon
Journal:  Fundam Clin Pharmacol       Date:  2013-07-16       Impact factor: 2.748

8.  Effects of cytochrome P450 (CYP)2C19 polymorphisms on pharmacokinetics of phenobarbital in neonates and infants with seizures.

Authors:  Soon Min Lee; Jae Yong Chung; Young Mock Lee; Min Soo Park; Ran Namgung; Kook In Park; Chul Lee
Journal:  Arch Dis Child       Date:  2012-02-13       Impact factor: 3.791

9.  Postoperative electroencephalographic seizures are associated with deficits in executive function and social behaviors at 4 years of age following cardiac surgery in infancy.

Authors:  J William Gaynor; Gail P Jarvik; Marsha Gerdes; Daniel S Kim; Ramakrishnan Rajagopalan; Judy Bernbaum; Gil Wernovsky; Susan C Nicolson; Thomas L Spray; Robert R Clancy
Journal:  J Thorac Cardiovasc Surg       Date:  2013-07       Impact factor: 5.209

10.  Antiepileptic drugs--best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies.

Authors:  Philip N Patsalos; David J Berry; Blaise F D Bourgeois; James C Cloyd; Tracy A Glauser; Svein I Johannessen; Ilo E Leppik; Torbjörn Tomson; Emilio Perucca
Journal:  Epilepsia       Date:  2008-07       Impact factor: 5.864

View more
  4 in total

1.  Pharmacokinetics of Commonly Used Medications in Children Receiving Continuous Renal Replacement Therapy: A Systematic Review of Current Literature.

Authors:  Samuel Dubinsky; Kevin Watt; Steven Saleeb; Bilal Ahmed; Caitlin Carter; Cindy H T Yeung; Andrea Edginton
Journal:  Clin Pharmacokinet       Date:  2021-11-30       Impact factor: 6.447

2.  Characteristics of Neonates with Cardiopulmonary Disease Who Experience Seizures: A Multicenter Study.

Authors:  Shavonne L Massey; Hannah C Glass; Renée A Shellhaas; Sonia Bonifacio; Taeun Chang; Catherine Chu; Maria Roberta Cilio; Monica E Lemmon; Charles E McCulloch; Janet S Soul; Cameron Thomas; Courtney J Wusthoff; Rui Xiao; Nicholas S Abend
Journal:  J Pediatr       Date:  2021-10-30       Impact factor: 4.406

Review 3.  What is the Best Predictor of Phenobarbital Pharmacokinetics to Use for Initial Dosing in Neonates?

Authors:  Martin Šíma; Danica Michaličková; Ondřej Slanař
Journal:  Pharmaceutics       Date:  2021-02-25       Impact factor: 6.321

4.  Population Pharmacokinetics of Phenobarbital in Neonates and Infants on Extracorporeal Membrane Oxygenation and the Influence of Concomitant Renal Replacement Therapy.

Authors:  Céline Thibault; Shavonne L Massey; Nicholas S Abend; Maryam Y Naim; Alexandra Zoraian; Athena F Zuppa
Journal:  J Clin Pharmacol       Date:  2020-09-22       Impact factor: 3.126

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.